Inhaled corticosteroid doses in asthma: an evidence‐based approach
H Powell, PG Gibson - Medical journal of Australia, 2003 - Wiley Online Library
H Powell, PG Gibson
Medical journal of Australia, 2003•Wiley Online LibraryObjective: To define the evidence for doses of inhaled corticosteroids in asthma and
describe this in clinically meaningful, evidence‐based terms. Data source: Cochrane
Database of Systematic Reviews. Study selection and data extraction: We identified
systematic reviews of randomised controlled trials of dosing of inhaled corticosteroids in
asthma. Data on efficacy and safety of different doses were extracted from meta‐analyses
and summarised as the number needed to treat (NNT) and number needed to harm (NNH) …
describe this in clinically meaningful, evidence‐based terms. Data source: Cochrane
Database of Systematic Reviews. Study selection and data extraction: We identified
systematic reviews of randomised controlled trials of dosing of inhaled corticosteroids in
asthma. Data on efficacy and safety of different doses were extracted from meta‐analyses
and summarised as the number needed to treat (NNT) and number needed to harm (NNH) …
Abstract
Objective: To define the evidence for doses of inhaled corticosteroids in asthma and describe this in clinically meaningful, evidence‐based terms.
Data source: Cochrane Database of Systematic Reviews.
Study selection and data extraction: We identified systematic reviews of randomised controlled trials of dosing of inhaled corticosteroids in asthma. Data on efficacy and safety of different doses were extracted from meta‐analyses and summarised as the number needed to treat (NNT) and number needed to harm (NNH).
Data synthesis: Inhaled corticosteroids were highly efficacious, with a relatively flat dose–response curve. Three patients needed to be treated with fluticasone 100 μg daily to prevent worsening asthma (NNT 3), and for fluticasone 1000 μg the NNT was 2.1 patients. The dose–response curve for side effects was steep. For a dose of fluticasone 100 μg, oral candidiasis developed in one of every 90 subjects treated (NNH 90). In contrast, the NNH for fluticasone 1000 μg and 2000 μg daily were 23 and 6, respectively.
Conclusion: Level 1 evidence supports the use of low‐dose inhaled corticosteroids in asthma. Clinicians should review doses of inhaled corticosteroids used for treating patients with asthma.
Wiley Online Library以上显示的是最相近的搜索结果。 查看全部搜索结果